|
|||||
|
|
Anti-Interleukin-6 Therapy Decreases Hip Synovitis and Bone Resorption and Increases Bone Formation Following Ischemic Osteonecrosis of the Femoral Head |
|
| Authors: | Yinshi Ren Zhuo Deng Vishal Gokani Michael Kutschke Thomas Wesley Mitchell Olumide Aruwajoye Naga Suresh Adapala Nobuhiro Kamiya Yousef Abu-Amer Harry KW Kim |
| Institution: | 1. Center for Excellence in Hip Disorders, Scottish Rite for Children, Dallas, TX, USA;2. Center for Excellence in Hip Disorders, Scottish Rite for Children, Dallas, TX, USA
Contribution: Data curation, Formal analysis, Investigation, Methodology, Validation;3. Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA Contribution: Data curation, Formal analysis, Methodology;4. Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA Contribution: Data curation;5. Center for Excellence in Hip Disorders, Scottish Rite for Children, Dallas, TX, USA Contribution: Data curation, Methodology;6. Department of Orthopaedic Surgery, Washington University, St. Louis, MO, USA Contribution: Investigation, Resources, Writing - review & editing |
| Abstract: | Legg-Calvé-Perthes disease (LCPD) is a juvenile form of ischemic femoral head osteonecrosis, which produces chronic hip synovitis, permanent femoral head deformity, and premature osteoarthritis. Currently, there is no medical therapy for LCPD. Interleukin-6 (IL-6) is significantly elevated in the synovial fluid of patients with LCPD. We hypothesize that IL-6 elevation promotes chronic hip synovitis and impairs bone healing after ischemic osteonecrosis. We set out to test if anti-IL-6 therapy using tocilizumab can decrease hip synovitis and improve bone healing in the piglet model of LCPD. Fourteen piglets were surgically induced with ischemic osteonecrosis and assigned to two groups: the no treatment group (n = 7) and the tocilizumab group (15 to 20 mg/kg, biweekly intravenous injection, n = 7). All animals were euthanized 8 weeks after the induction of osteonecrosis. Hip synovium and femoral heads were assessed for hip synovitis and bone healing using histology, micro-CT, and histomorphometry. The mean hip synovitis score and the number of synovial macrophages and vessels were significantly lower in the tocilizumab group compared with the no treatment group (p < .0001, p = .01, and p < .01, respectively). Micro-CT analysis of the femoral heads showed a significantly higher bone volume in the tocilizumab group compared with the no treatment group (p = .02). The histologic assessment revealed a significantly lower number of osteoclasts per bone surface (p < .001) in the tocilizumab group compared with the no treatment group. Moreover, fluorochrome labeling showed a significantly higher percent of mineralizing bone surface (p < .01), bone formation rate per bone surface (p < .01), and mineral apposition rate (p = .04) in the tocilizumab group. Taken together, tocilizumab therapy decreased hip synovitis and osteoclastic bone resorption and increased new bone formation after ischemic osteonecrosis. This study provides preclinical evidence that tocilizumab decreases synovitis and improves bone healing in a large animal model of LCPD. © 2020 American Society for Bone and Mineral Research (ASBMR). |
| Keywords: | FEMORAL HEAD OSTEONECROSIS AVASCULAR NECROSIS LEGG-CALVÉ-PERTHES DISEASE INTERLEUKIN-6 INTERLEUKIN-6 RECEPTOR INHIBITOR TOCILIZUMAB |